Skip to the page

Data / Form D filings / Shenandoah Therapeutics Inc.

Shenandoah Therapeutics Inc.: Form D filing

Shenandoah Therapeutics Inc., a technology company in South San Francisco, CA, filed a Form D with the SEC in 2025. The latest, on May 15, 2025, reports $21.5 million sold of a $21.5 million offering to 12 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
329 OYSTER POINT BLVD., 3RD FLOOR, South San Francisco, CA, 94080
Phone
(650) 239-0503
Industry
Other Technology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2022
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2068421

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
May 15, 2025New notice$21,499,989$21,499,98912May 2, 2025sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Mark StepkaExecutive Officer
Gary YeungDirector
Isabella GraefExecutive Officer, Director
Wendy YoungDirector
Nathanael GrayDirector
Jim EdwardsDirector

Other technology companies in California that filed recently

Every Form D from the week of May 12, 2025 · All recent filings in California · All recent Other Technology filings

Read from SEC EDGAR. Amount sold is what Shenandoah Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.